

Institutional Biosafety Committee (IBC)

Meeting Minutes

| Institution: | Wake Forest University School of Medicine | | | |
|-------------------------------|--|--|---|--|
| Meeting Date and Time: | June 18 th , 2025 | | | |
| Meeting Type: | Online via Microsoft Teams | | | |
| | Name | Role and Department | Attendance | |
| IBC Members Present: | Frank Marini, PhD | IBC Chair, WFIRM | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Gagan Deep, PhD | IBC Member, Cancer Biology | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Christopher Edwards, MD | IBC Member, Anesthesiology | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Ji Hyun Kim, PhD | IBC Member, WFIRM | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Sam Centanni, PhD | IBC Member, Translational Neuro | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Elizabeth Palavecino, MD | IBC Member, Pathology | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Marlena Westcott, MD | IBC Member, Microbiology & Immunology | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Brian Strittmatter, PharmD | IBC Member, Pharmacy Clinical Trial Services | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Chris Ohl, MD | IBC Member, Infectious Diseases | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | David Ornelles, PhD | IBC Member – Past Chair, Microbiology & Immunology | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Patrick McNutt, PhD | IBC Member, WFIRM | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Linda Metheny-Barlow, PhD | IBC Member, Radiation Oncology | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Swapan Das, PhD, MSc | IBC Member, Endocrinology | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Caryn Gee Morse, MD, MPH | IBC Member, Infectious Diseases | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Drew Kiraly, MD | IBC Member, Translational Neuro | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Graca Almeida-Porada, MD, PhD | IBC Member, WFIRM | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Robert Hampson, PhD | IBC Member, WFIRM | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Ex Officio Members without Vote | | | |
| | Jessica Baker | IACUC | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Tara McGee-Walker | WFSM Teammate Health | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |

| | | | | |
|--|---|------------------------------------|---|--|
| | Scott Gamble, DVM | Animal Resources Program | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Gaye Hodges | Animal Resources Program | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Suzy Mounsey | Animal Resources Program | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Paul Hysell | WFU Representative | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Stephen Fisenne | WFU Representative | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Mei-Chuan Ko, PhD | Salisbury VA Representative | <input type="checkbox"/> Present | <input checked="" type="checkbox"/> Absent |
| | Morgan Lawson | Environmental Health & Safety | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Bernadette Menuey | BSO, Environmental Health & Safety | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Emylee Pedersen | Environmental Health & Safety | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Kara Milton | Community Representative | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Adam Bray | Community Representative | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Jennifer Williams | Environmental Health & Safety | <input checked="" type="checkbox"/> Present | <input type="checkbox"/> Absent |
| | Quorum: | Yes | | |
| Call to Order: | IBC chair called meeting to order at 12:30 | | | |
| Conflicts of Interest: | Chair reminded all members present to identify any conflicts of interest as protocols are reviewed. No COIs to disclose for this meeting. | | | |
| Review and Approval of Previous Meeting Minutes: | Motion to approve by Dr. Marini, second by Dr. McNutt | | | |
| Review of Prior Meeting Business (if applicable): | BSL 3 Laboratory is currently undergoing annual maintenance. Dual Use Research of Concern Update: <ul style="list-style-type: none">Wake policy has been drafted. New executive order was issued regarding timelines for implementation of DURC oversight. Wake will move forward with implementation DURC/PEPP oversight police issued in 2024. | | | |
| New IBC Registrations and Amendments for Review | | | | |
| PI Name: | Li Tan | | | |
| Registration Number: | 05.2025.PlasticRS.010000.793.01 | | | |
| IBC Registration Title: | Impregnation of [REDACTED] on breast implants to reduce implant-associated infections in mice | | | |
| Project Overview: | Investigation of biofilm (<i>S. aureus</i>) coated and uncoated breast implants. | | | |
| Applicable NIH Guidelines: | Not applicable | | | |
| Agent Description: e.g. virulence, pathogenicity, environmental stability | [REDACTED] | | | |
| Types of Manipulations: | Not Applicable | | | |

| | |
|---|---|
| Source of nucleic (DNA/RNA) sequences: e.g. species | Not Applicable |
| Nature of nucleic acid sequences: e.g. structural gene, oncogene | Not Applicable |
| Host(s) and Vector(s): | Not Applicable |
| Will a transgene be expressed? If so, what is the function of the protein that will be produced? | Not Applicable |
| Risk Assessment Discussion Points: | Researchers should ensure appropriate sanitation practices following IVIS imaging. Waste practices should follow institutional requirements for biohazard waste. All researchers must submit required biosafety training records. |
| Training: | Initial Biosafety Training Animal Biosafety (AALAS Biosafety course certificate can be submitted in lieu of CITI training for animal work) Emergency and Incident Response to Biohazard Spills and Releases |
| Occupational Health Review (if applicable): | Not applicable |
| Biosafety Level: Animal Biosafety Level: | BSL 2/ABSL 2 |
| IBC Vote: | Approved at BSL/ABSL 2 pending modifications. |
| | |
| PI Name: | Bernal-Mizrachi |
| Registration Number: | 04.2025.HemOnc.110000.794.01 |
| IBC Registration Title: | ██████████: Biology, Biomarker Design, and Therapeutic Applications |
| Project Overview: | Investigation the role of ██████████ in spreading drug resistance among cancer cells; produce therapeutic peptides and fusion proteins that target cancer cells designed to inhibit key pathways to tumor growth or selective cytotoxicity |
| Applicable NIH Guidelines: | Section III-E |
| Agent Description: e.g. virulence, pathogenicity, environmental stability | ██████████ Third generation packaging system |
| Types of Manipulations: | Infection of cells using ██████████ to knock out gene of interest and chemically mediated transfection methods. These technologies will introduce mutants of candidate genes of mammalian cells with recombinant DNA constructs. We aim to produce therapeutic peptides designed to inhibit key pathways in tumor |

| | |
|---|---|
| | growth or promote selective cytotoxicity. The proteins produced will include cell-penetrating peptides (CPPs) or chimeric fusion proteins with targeting sequences, which will be assessed for their ability to specifically bind and interfere with cancer-related cellular mechanisms. Expression systems such as HEK293 cells may be used for large-scale production, and purification will be carried out using affinity chromatography or size-exclusion chromatography to isolate the desired protein for further functional assays or therapeutic applications. |
| Source of nucleic (DNA/RNA) sequences: e.g. species | Proprietary [REDACTED] |
| Nature of nucleic acid sequences: e.g. structural gene, oncogene | Human tumor cells |
| Host(s) and Vector(s): | Host: Mammalian Vector: [REDACTED] |
| Will a transgene be expressed? If so, what is the function of the protein that will be produced? | KRAS – cell growth NRAS – cell growth and regulation P53 – Tumor Suppressor NFKB2 – signaling pathway hnRNPU – RNA processing FMR1 – FMRP Protein development MMTAG2 – multiple myeloma tumor associated protein LSM14 - LSM14A mRNA Processing Body Assembly Factor MARCH9 - Membrane Associated Ring-CH-Type Finger MKK4 – signaling pathway TIAM1- T-lymphoma invasion and metastasis-inducing protein encoder MCF2L - encodes a protein that acts as a guanine nucleotide exchange factor (GEF) MYB - encodes transcription factors that play crucial roles in various cellular processes, including cell proliferation, differentiation, and apoptosis |
| Risk Assessment Discussion Points: | Protocol has been revised per committee request and training documents were received. |
| Training: | Awaiting training certifications from PI for: <ul style="list-style-type: none"> • Initial Biosafety Training • Biosafety Retraining • Animal Biosafety • Emergency and Incident Response to Biohazard Spills and Releases • NIH Recombinant DNA Guidelines • OSHA Bloodborne Pathogens |
| Occupational Health Review (if applicable): | Not applicable |
| Biosafety Level: Animal Biosafety Level: | BSL 2/ABSL 1 |
| IBC Vote: | IBC Chair motioned to approve protocol at BSL 2 pending modifications. |
| Other | |

| | |
|--------------------------------|--|
| New Business: | None |
| Review of Incidents: | No biological incidents to review. |
| Lab Assessments Update: | Not Applicable |
| IBC Training: | Not applicable |
| Public Comments: | No public comments |
| Adjournment: | IBC chair adjourned meeting at 1:07 pm |